A phase II randomized trial of lapatinib with either vinorelbine or capecitabine in ErbB2-overexpressing first- and second-line metastatic breast cancer (MBC).W Janni, Jose Alvarez, C.A. Papadimitriou et al.|Journal of Clinical Oncology|2010Cited by 2